InsiderTrades.com logo
Musk Says ‘Dollar Will Be Worth Nothing…’
From Crypto 101 Media   |   Ad
Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025
Click here to reserve your seat at the Crypto Community Summit.
Bradford D. Dahms net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Bradford Dahms Biography and Net Worth

CFO of Theseus Pharmaceuticals
Bradford D. Dahms occupies the position of Chief Financial Officer for Theseus Pharmaceuticals, Inc.

In the past he was Chief Financial & Accounting Officer for Selecta Biosciences, Inc., Analyst at JPMorgan Chase & Co. and Senior VP-Healthcare Investment Banking at Cantor Fitzgerald & Co.

He received an undergraduate degree from The Ohio State University.

What is Bradford D. Dahms' net worth?

The estimated net worth of Bradford D. Dahms is at least $24,936.52 as of November 30th, 2022. Mr. Dahms owns 6,142 shares of Theseus Pharmaceuticals stock worth more than $24,937 as of November 14th. This net worth estimate does not reflect any other assets that Mr. Dahms may own. Additionally, Mr. Dahms receives a salary of $480,950.00 as CFO at Theseus Pharmaceuticals. Learn More about Bradford D. Dahms' net worth.

How old is Bradford D. Dahms?

Mr. Dahms is currently 36 years old. There are 1 older executives and no younger executives at Theseus Pharmaceuticals. Learn More on Bradford D. Dahms' age.

What is Bradford D. Dahms' salary?

As the CFO of Theseus Pharmaceuticals, Inc., Mr. Dahms earns $480,950.00 per year. Learn More on Bradford D. Dahms' salary.

How do I contact Bradford D. Dahms?

The corporate mailing address for Mr. Dahms and other Theseus Pharmaceuticals executives is , , . Theseus Pharmaceuticals can also be reached via phone at 857-400-9491 and via email at [email protected]. Learn More on Bradford D. Dahms' contact information.

Has Bradford D. Dahms been buying or selling shares of Theseus Pharmaceuticals?

Bradford D. Dahms has not been actively trading shares of Theseus Pharmaceuticals during the last ninety days. Most recently, on Wednesday, November 30th, Bradford D. Dahms bought 1,502 shares of Theseus Pharmaceuticals stock. The stock was acquired at an average cost of $6.66 per share, with a total value of $10,003.32. Following the completion of the transaction, the chief financial officer now directly owns 6,142 shares of the company's stock, valued at $40,905.72. Learn More on Bradford D. Dahms' trading history.

Who are Theseus Pharmaceuticals' active insiders?

Theseus Pharmaceuticals' insider roster includes Timothy Clackson (CEO), Bradford Dahms (CFO), and Carl Gordon (Director). Learn More on Theseus Pharmaceuticals' active insiders.

Bradford D. Dahms Insider Trading History at Theseus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2022Buy1,502$6.66$10,003.326,142View SEC Filing Icon  
12/21/2021Buy1,970$10.15$19,995.50View SEC Filing Icon  
See Full Table

Bradford D. Dahms Buying and Selling Activity at Theseus Pharmaceuticals

This chart shows Bradford D Dahms's buying and selling at Theseus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Theseus Pharmaceuticals Company Overview

Theseus Pharmaceuticals logo
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Read More

Today's Range

Now: $4.06
Low: $4.06
High: $4.06

50 Day Range

MA: $4.06
Low: $4.06
High: $4.07

2 Week Range

Now: $4.06
Low: $2.05
High: $12.37

Volume

N/A

Average Volume

592,167 shs

Market Capitalization

$179.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.98
Musk Says ‘Dollar Will Be Worth Nothing…’
From Crypto 101 Media   |   Ad
Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025
Click here to reserve your seat at the Crypto Community Summit.